Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cencora inc. - COR

COR

Close Chg Chg %
335.10 2.55 0.76%

Closed Market

337.65

+2.55 (0.76%)

Volume: 1.28M

Last Updated:

Dec 4, 2025, 3:59 PM EDT

Trade Now

Company Overview: cencora inc. - COR

COR Key Data

Open

$335.14

 Day Range

334.00 - 338.10

52 Week Range

223.92 - 377.53

 Market Cap

$65.05B

Shares Outstanding

193.99M

 Public Float

N/A

Beta

0.63

 Rev. Per Employee

N/A

P/E Ratio

44.05

 EPS

$8.02

Yield

64.16%

 Dividend

$0.60

EX-DIVIDEND DATE

Nov 14, 2025

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.74M

  

COR Performance

1 Week
 
 -8.48%
 
1 Month
 
 -6.40%
 
3 Months
 
 15.43%
 
1 Year
 
 38.71%
 
5 Years
 
 227.86%
 

COR Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 19
Full Ratings ➔

About cencora inc. - COR

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

COR At a Glance

Cencora, Inc.
1 West First Avenue
Conshohocken, Pennsylvania 19428-1800
Phone 1-610-727-7000 Revenue 321.33B
Industry Medical Distributors Net Income 1.55B
Sector Distribution Services 2025 Sales Growth 9.312%
Fiscal Year-end 09 / 2026 Employees 51,000
View SEC Filings

COR Valuation

P/E Current 44.046
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 39.256
Price to Sales Ratio 0.19
Price to Book Ratio 40.193
Price to Cash Flow Ratio 15.74
Enterprise Value to EBITDA 14.064
Enterprise Value to Sales 0.206
Total Debt to Enterprise Value 0.141

COR Efficiency

Revenue/Employee 6,300,643.51
Income Per Employee 30,473.902
Receivables Turnover 12.739
Total Asset Turnover 4.473

COR Liquidity

Current Ratio 0.903
Quick Ratio 0.549
Cash Ratio 0.076

COR Profitability

Gross Margin 3.156
Operating Margin 1.135
Pretax Margin 0.703
Net Margin 0.484
Return on Assets 2.163
Return on Equity 144.308
Return on Total Capital 14.338
Return on Invested Capital 19.482

COR Capital Structure

Total Debt to Total Equity 618.77
Total Debt to Total Capital 86.087
Total Debt to Total Assets 12.183
Long-Term Debt to Equity 594.132
Long-Term Debt to Total Capital 82.659
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cencora Inc. - COR

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
238.59B 262.17B 293.96B 321.33B
Sales Growth
+11.50% +9.89% +12.12% +9.31%
Cost of Goods Sold (COGS) incl D&A
230.99B 254.42B 285.26B 311.19B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
697.94M 972.39M 1.11B 1.06B
Depreciation
390.64M 418.83M 448.20M 501.31M
Amortization of Intangibles
307.30M 553.56M 663.47M 556.93M
COGS Growth
+11.20% +10.14% +12.12% +9.09%
Gross Income
7.60B 7.76B 8.70B 10.14B
Gross Income Growth
+21.24% +2.05% +12.18% +16.55%
Gross Profit Margin
+3.19% +2.96% +2.96% +3.16%
2022 2023 2024 2025 5-year trend
SG&A Expense
4.85B 5.31B 5.66B 6.49B
Research & Development
- - - -
-
Other SG&A
4.85B 5.31B 5.66B 6.49B
SGA Growth
+34.91% +9.51% +6.61% +14.71%
Other Operating Expense
- - - -
-
Unusual Expense
380.46M 105.54M 827.00M 1.05B
EBIT after Unusual Expense
2.37B 2.34B 2.21B 2.59B
Non Operating Income/Expense
43.83M 95.51M 39.52M 85.00M
Non-Operating Interest Income
21.31M 46.72M 91.69M 128.21M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
231.98M 275.65M 248.68M 419.75M
Interest Expense Growth
+27.08% +18.82% -9.78% +68.79%
Gross Interest Expense
231.98M 275.65M 248.68M 419.75M
Interest Capitalized
- - - -
-
Pretax Income
2.18B 2.16B 2.00B 2.26B
Pretax Income Growth
-1.75% -1.02% -7.26% +12.69%
Pretax Margin
+0.91% +0.82% +0.68% +0.70%
Income Tax
516.52M 428.26M 484.70M 690.52M
Income Tax - Current - Domestic
166.25M 302.06M 389.42M 430.36M
Income Tax - Current - Foreign
154.08M 245.06M 197.61M 200.30M
Income Tax - Deferred - Domestic
181.46M 3.85M (16.54M) 82.30M
Income Tax - Deferred - Foreign
14.73M (122.71M) (85.78M) (22.44M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.67B 1.73B 1.52B 1.57B
Minority Interest Expense
(32.28M) (12.72M) 10.15M 13.64M
Net Income
1.70B 1.75B 1.51B 1.55B
Net Income Growth
+10.32% +2.74% -13.53% +2.99%
Net Margin Growth
+0.71% +0.67% +0.51% +0.48%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
1.70B 1.75B 1.51B 1.55B
Preferred Dividends
- - - -
-
Net Income Available to Common
1.70B 1.75B 1.51B 1.55B
EPS (Basic)
8.1489 8.6183 7.6025 8.0186
EPS (Basic) Growth
+8.97% +5.76% -11.79% +5.47%
Basic Shares Outstanding
208.47M 202.51M 198.50M 193.82M
EPS (Diluted)
8.0433 8.5306 7.5349 7.9614
EPS (Diluted) Growth
+8.88% +6.06% -11.67% +5.66%
Diluted Shares Outstanding
211.21M 204.59M 200.28M 195.21M
EBITDA
3.45B 3.42B 4.15B 4.71B
EBITDA Growth
+8.47% -0.89% +21.44% +13.35%
EBITDA Margin
+1.45% +1.30% +1.41% +1.46%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 389.571
Number of Ratings 19 Current Quarters Estimate 4.069
FY Report Date 12 / 2025 Current Year's Estimate 17.663
Last Quarter’s Earnings 3.84 Median PE on CY Estimate N/A
Year Ago Earnings 16.00 Next Fiscal Year Estimate 19.531
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 16 14
Mean Estimate 4.07 4.91 17.66 19.53
High Estimates 4.39 5.03 18.02 20.19
Low Estimate 3.89 4.72 17.51 19.18
Coefficient of Variance 3.78 1.51 0.66 1.43

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 11
OVERWEIGHT 2 2 2
HOLD 5 4 4
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Cencora Inc. - COR

Date Name Shares Transaction Value
Sep 19, 2025 Steven H. Collis Executive Chairman; Director 337,263 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $86.09 per share 29,034,971.67
Sep 19, 2025 Steven H. Collis Executive Chairman; Director 305,913 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $289.86 per share 88,671,942.18
Sep 19, 2025 Steven H. Collis Executive Chairman; Director 58,699 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 8, 2025 Elizabeth S. Campbell Executive Vice President 14,710 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $254.87 per share 3,749,137.70
Jul 8, 2025 Silvana Battaglia Executive Vice President 11,349 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $254.87 per share 2,892,519.63
Mar 21, 2025 Robert P. Mauch President & CEO; Director 38,702 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2025 Robert P. Mauch President & CEO; Director 49,326 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.93 per share 12,870,633.18
Mar 21, 2025 Robert P. Mauch President & CEO; Director 51,070 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.93 per share 13,325,695.10
Mar 21, 2025 Robert P. Mauch President & CEO; Director 54,296 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $86.09 per share 4,674,342.64
Mar 12, 2025 Lazarus Krikorian SVP & Chief Accounting Officer 20,154 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $260.06 per share 5,241,249.24
Mar 11, 2025 Redonda G. Miller Director 3,194 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 D. Mark Durcan Director 22,862 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Lorence H. Kim Director 3,524 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Franklin K. Clyburn Director 1,157 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Lauren M. Tyler Director 2,771 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Werner Baumann Director 2,771 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Dennis M. Nally Director 13,130 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Lon R. Greenberg Director 20,851 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 3, 2025 Steven H. Collis Executive Chairman; Director 163,520 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Cencora Inc. in the News